Owners, management and financials
CVR: 43773070
Previous names: Synobody ApS
DKK 2,352,263
Gross profit
Net result: DKK -292,800
Arvedsen & Faliu Holding ApS (100%)
CVR · view owners
Emil Arvedsen, Jannik Faliu
CVR · view management
Active
Founded 12 January 2023
CVR · view overview
5 employees
Annual report 2025 · average
Owner registered: Arvedsen & Faliu Holding ApS
CVR · 20/05/2026
View the full event history
Immunordic ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Synobody ApS. The management consists of Emil Arvedsen and Jannik Faliu. The company is owned by Arvedsen & Faliu Holding ApS. According to the 2025 annual report, the company had an average of 5 employees. In 2025, the company reported a gross profit of DKK 2,352,263 and a net result of DKK -292,800 compared with DKK 7,762 the year before. Equity in the 2025 report amounted to DKK 606,284.
Source: annual report 2025, Danish Business Authority
Immunordic ApS shows a mixed financial health trajectory since its inception in 2023, with gross profit increasing from 540,638 DKK in 2023 to 2,352,263 DKK in 2025, indicating strong growth in profitability. However, the company has experienced net losses in its first two years, culminating in a loss of 292,800 DKK in 2025, raising concerns about its sustainability. Equity has fluctuated, starting at -8,678 DKK in 2023 and improving to 606,284 DKK by 2025, suggesting a recovery but still highlighting the need for careful management of financial resources. As a newly established entity in the research and experimental development sector, its future success will depend on maintaining this growth trajectory while achieving consistent profitability.
AI-generated summary · Generated 14/08/2026
Selskabets formål er direkte eller indirekte at drive bioteknologi-virksomhed, herunder forskning, eksperimentel udvikling og salg af antistoffer, herunder single-domain antistoffer, samt al virksomhed, som efter direktionens skøn har forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 2.4 mio. | -293 t. | 5.9 mio. | 606 t. | 5 | |
| 202401/01/2024 – 31/12/2024 | 956 t. | 8 t. | 3.6 mio. | 899 t. | 3 | |
| 202312/01/2023 – 31/12/2023 | 541 t. | -49 t. | 1.1 mio. | -9 t. | 2 |
Compared to 1.040 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorThe CVR number of Immunordic ApS is 43773070.
Immunordic ApS is owned by Arvedsen & Faliu Holding ApS.
The management of Immunordic ApS consists of Emil Arvedsen and Jannik Faliu.
In 2025, Immunordic ApS reported a gross profit of DKK 2,352,263.
Immunordic ApS had an average of 5 employees in the 2025 financial year according to the annual report.
Immunordic ApS was founded on 12 January 2023.
Claim this page to add your logo and social links. Free to get started.
Immunordic ApS has published its annual report for 2025. Gross profit came to DKK 2,352,263, and the net result was DKK -292,800.
As of May 20, 2026, Arvedsen & Faliu Holding ApS is registered as an owner of Immunordic ApS with an ownership share of 100%.
Immunordic ApS has published its annual report for 2024. Gross profit came to DKK 955,745, and the net result was DKK 7,762.
On November 1, 2024, the company changed its name from Synobody ApS to Immunordic ApS.
Immunordic ApS has published its annual report for 2023. Gross profit came to DKK 540,638, and the net result was DKK -48,678.
As of January 12, 2023, Emil Arvedsen is registered as director of Immunordic ApS.
As of January 12, 2023, Jannik Faliu is registered as director of Immunordic ApS.
Immunordic ApS was founded on January 12, 2023.
Companies in the same industry and area
CVR 26333210
CVR 26392861
CVR 41366044
CVR 27701396
CVR 33992890
